Targeting of CD34(+)CD38(-) cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in acute Myeloid Leukaemia

BACKGROUND: The CD34(+)CD38(-) subset of AML cells is enriched for resistance to current chemotherapeutic agents and considered to contribute to disease progression and relapse in Acute Myeloid Leukaemia (AML) patients following initial treatment. METHODS: Chemosensitivity in phenotypically defined...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Jawad, Mays, Yu, Ning, Seedhouse, Claire, Tandon, Karuna, Russell, Nigel H, Pallis, Monica
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2012
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3488582/
https://ncbi.nlm.nih.gov/pubmed/23013471
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-12-431
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller